PE20081215A1 - Identificacion y caracterizacion de variantes de replicon de vhc con menor susceptibilidad a vhc-796, y metodos relacionados - Google Patents

Identificacion y caracterizacion de variantes de replicon de vhc con menor susceptibilidad a vhc-796, y metodos relacionados

Info

Publication number
PE20081215A1
PE20081215A1 PE2007001141A PE2007001141A PE20081215A1 PE 20081215 A1 PE20081215 A1 PE 20081215A1 PE 2007001141 A PE2007001141 A PE 2007001141A PE 2007001141 A PE2007001141 A PE 2007001141A PE 20081215 A1 PE20081215 A1 PE 20081215A1
Authority
PE
Peru
Prior art keywords
hcv
characterization
identification
hepatitis
related methods
Prior art date
Application number
PE2007001141A
Other languages
English (en)
Inventor
Anita Y M Howe
Rajiv Chopra
Original Assignee
Wyeth Corp
Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Viropharma Inc filed Critical Wyeth Corp
Publication of PE20081215A1 publication Critical patent/PE20081215A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN METODO PARA DISMINUIR LA FRECUENCIA DE APARICION DE UNA INFECCION VIRAL DE HEPATITIS C RESISTENTE AL TRATAMIENTO QUE COMPRENDE ADMINISTRAR A) UN BENZOFURANO QUE ES INHIBIDOR DEL VIRUS DE LA HEPATITIS C TAL COMO 5-CICLOPROPIL-2-(4-FLUOROFENIL)-6-[(2-HIDROXIETIL)(METILSULFONIL)AMINO]-N-METIL-1-BENZOFURAN-3-CARBOXAMIDA (VHC-796); Y B) UN AGENTE ANTI-VIRUS DE LA HEPATITIS C QUE ES UN INMUNOMODULADOR TAL COMO RIBAVIRINA. SE REFIERE TAMBIEN A METODOS PARA IDENTIFICAR INDIVIDUOS CON MENOR PROBABILIDAD DE RESPONDER A UN TRATAMIENTO CONTRA LA HEPATITIS C VIRAL
PE2007001141A 2006-08-25 2007-08-22 Identificacion y caracterizacion de variantes de replicon de vhc con menor susceptibilidad a vhc-796, y metodos relacionados PE20081215A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84035306P 2006-08-25 2006-08-25

Publications (1)

Publication Number Publication Date
PE20081215A1 true PE20081215A1 (es) 2008-10-22

Family

ID=39022157

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001141A PE20081215A1 (es) 2006-08-25 2007-08-22 Identificacion y caracterizacion de variantes de replicon de vhc con menor susceptibilidad a vhc-796, y metodos relacionados

Country Status (9)

Country Link
US (2) US20080182895A1 (es)
AR (1) AR062482A1 (es)
AU (1) AU2007286754A1 (es)
BR (1) BRPI0715714A2 (es)
CA (1) CA2659461A1 (es)
CL (1) CL2007002447A1 (es)
PE (1) PE20081215A1 (es)
TW (1) TW200816990A (es)
WO (1) WO2008024763A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102614510A (zh) * 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
EP2101173A1 (en) * 2008-03-14 2009-09-16 Vivalis In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
FR2933094A1 (fr) * 2008-06-26 2010-01-01 Univ Joseph Fourier Mutations dans la proteine ns5b du vhc.
WO2010033841A1 (en) * 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
DE102014219858B4 (de) 2014-09-30 2021-09-23 Aktiebolaget Skf Kreuzgelenk
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
GB201704386D0 (en) * 2017-03-20 2017-05-03 Univ London Queen Mary Method for identification of sofosbuvir resistant patients

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010079907A (ko) * 1998-09-25 2001-08-22 비로파마 인코포레이티드 바이러스 감염 및 관련 질병의 치료 및 예방 방법
DE10030139A1 (de) * 2000-06-20 2002-01-10 Cmi Ag Verwendung von Phyllanthusbesandteilen zur Behandlung oder Prophylaxe von Infekten durch Flaviviridae
CN102372764A (zh) * 2000-07-21 2012-03-14 先灵公司 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
JP2004529080A (ja) * 2000-10-25 2004-09-24 アグネッロ，ヴィンセント Ｈｃｖ、他のフラビウイルス科ウイルス、および血液中で低密度リポタンパク質または超低密度リポタンパク質と複合体を形成するその他のあらゆるウイルスによる感染を細胞中へのウイルス侵入を抑制することによって防止する方法
AU2002232660A1 (en) * 2000-12-15 2002-06-24 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
TW200400818A (en) * 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
TW200400963A (en) * 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
MXPA04012802A (es) * 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
US20040067877A1 (en) * 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
US20050159345A1 (en) * 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
US7842719B2 (en) * 2002-10-31 2010-11-30 Kemin Foods, L.C. Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus
WO2004041201A2 (en) * 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
MXPA05005192A (es) * 2002-11-15 2005-09-08 Idenix Cayman Ltd Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae.
CN100347184C (zh) * 2003-01-07 2007-11-07 凯敏制药欧洲股份有限公司 可用于治疗由黄病毒科病毒如丙型肝炎及牛病毒性腹泻病毒引起的感染的双环糖类化合物
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
WO2005000308A2 (en) * 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
AU2004258750A1 (en) * 2003-07-25 2005-02-03 Centre National De La Recherche Scientifique -Cnrs Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
TW200528459A (en) * 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
JP2005202801A (ja) * 2004-01-16 2005-07-28 Sharp Corp 表示装置
WO2006000922A2 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
US20060035848A1 (en) * 2004-08-09 2006-02-16 Zymetx, Inc. Broad-spectrum inhibitor of viruses in the Flaviviridae family
TWM262874U (en) * 2004-08-10 2005-04-21 Starlink Electronics Corp LGA terminal structure with changed circuit
JP2008514611A (ja) * 2004-09-23 2008-05-08 ワイス Ｃ型肝炎ウイルスによる感染を処置するためのカルバゾールおよびシクロペンタインドールの誘導体
KR20080059270A (ko) * 2005-09-30 2008-06-26 싸이넥시스, 인크. Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물
US20070128270A1 (en) * 2005-11-10 2007-06-07 Wyeth Pharmaceutical formulations containing 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide and method of making the same
US20070265335A1 (en) * 2005-11-10 2007-11-15 Wyeth Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsufonyl)amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same
TW200808308A (en) * 2006-02-09 2008-02-16 Schering Corp Novel HCV inhibitor combinations and methods
TW200815384A (en) * 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein

Also Published As

Publication number Publication date
CA2659461A1 (en) 2008-02-28
TW200816990A (en) 2008-04-16
BRPI0715714A2 (pt) 2014-03-11
US20100028922A1 (en) 2010-02-04
AR062482A1 (es) 2008-11-12
US20080182895A1 (en) 2008-07-31
CL2007002447A1 (es) 2008-03-14
WO2008024763A3 (en) 2008-12-24
AU2007286754A1 (en) 2008-02-28
WO2008024763A2 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
PE20081215A1 (es) Identificacion y caracterizacion de variantes de replicon de vhc con menor susceptibilidad a vhc-796, y metodos relacionados
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA200700243A1 (ru) Способы лечения гепатита с
CL2013000791A1 (es) Compuestos derivados prolinas macrociclicas, inhibidores de las proteasas de serina, en particular proteasa ns3-ns4a, del virus de la hepatitis c (vhc); composicion que los comprende; y metodo de tratamiento de una infeccion viral por vhc.
UY28525A1 (es) Péptidos macrociclicos activos contra en virus de la hepatitis c
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
EA200900298A1 (ru) Ингибиторы вируса гепатита с
CO6761348A2 (es) Compuestos antivirales
NO20090453L (no) Hepatitt C Virusinhibitorer
MA32634B1 (fr) Polytherapie destinee a traiter une infection par le vhc
EA201000556A1 (ru) Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
PE20090228A1 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
BRPI0913012A2 (pt) vírus do nilo ocidental/da dengue quiméricos
WO2010047830A3 (en) Agents for hcv treatment
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
WO2008118849A3 (en) Hiv-1 protease inhibitors
PH12016500465A1 (en) Deoxynojirimycin derivatives and methods of their using
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
WO2012061248A8 (en) Novel specific hcv ns3 protease inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal